ADC dealmaking is red hot. Is it sustainable?
The frenzied dealmaking for antibody-drug conjugates is far from over.
In the past 10 days, there’s been a slew of ADC deals. Genmab made its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
